These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 26631878)

  • 1. Efficacy of Prophylactic G-CSF in Patients Receiving FOLFIRINOX: A Preliminary Retrospective Study.
    Terazawa T; Goto M; Miyamoto T; Asaishi K; Shimamoto F; Kuwakado S; Nishitani H; Kii T; Higuchi K
    Intern Med; 2015; 54(23):2969-73. PubMed ID: 26631878
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Real-world safety and supportive care use of second-line 5-fluorouracil-based regimens among patients with metastatic pancreatic ductal adenocarcinoma.
    Kim G; Cockrum P; Surinach A; Wang S; Wainberg Z
    Curr Med Res Opin; 2022 Aug; 38(8):1295-1303. PubMed ID: 35354375
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Optimal dose reduction of FOLFIRINOX for preserving tumour response in advanced pancreatic cancer: Using cumulative relative dose intensity.
    Lee JC; Kim JW; Ahn S; Kim HW; Lee J; Kim YH; Paik KH; Kim J; Hwang JH
    Eur J Cancer; 2017 May; 76():125-133. PubMed ID: 28324747
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of granulocyte colony-stimulating factor on FOLFIRINOX-induced neutropenia prevention: A population pharmacokinetic/pharmacodynamic approach.
    Macaire P; Paris J; Vincent J; Ghiringhelli F; Bengrine-Lefevre L; Schmitt A
    Br J Clin Pharmacol; 2020 Dec; 86(12):2473-2485. PubMed ID: 32386071
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A randomized, placebo-controlled phase ii study evaluating the reduction of neutropenia and febrile neutropenia in patients with colorectal cancer receiving pegfilgrastim with every-2-week chemotherapy.
    Hecht JR; Pillai M; Gollard R; Heim W; Swan F; Patel R; Dreiling L; Mo M; Malik I
    Clin Colorectal Cancer; 2010 Apr; 9(2):95-101. PubMed ID: 20378503
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Two cases of pancreatic cancer treated with FOLFIRINOX regimen and G-CSF prophylaxis at the standard therapeutic dose].
    Kiba T; Okada Y; Kajiume S; Yamaguchi A
    Gan To Kagaku Ryoho; 2015 May; 42(5):629-32. PubMed ID: 25981661
    [TBL] [Abstract][Full Text] [Related]  

  • 7. 2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours.
    Aapro MS; Bohlius J; Cameron DA; Dal Lago L; Donnelly JP; Kearney N; Lyman GH; Pettengell R; Tjan-Heijnen VC; Walewski J; Weber DC; Zielinski C;
    Eur J Cancer; 2011 Jan; 47(1):8-32. PubMed ID: 21095116
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Primary prophylactic granulocyte colony-stimulating factor according to ASCO guidelines has no preventive effect on febrile neutropenia in patients treated with docetaxel, cisplatin, and 5-fluorouracil chemotherapy.
    Kawahira M; Yokota T; Hamauchi S; Kawai S; Yoshida Y; Onozawa Y; Tsushima T; Todaka A; Machida N; Yamazaki K; Fukutomi A; Yasui H
    Int J Clin Oncol; 2018 Dec; 23(6):1189-1195. PubMed ID: 29948238
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [A Pancreatic Cancer Patient in Whom Pegfilgrastim Prophylaxis Did Not Prevent Severe Neutropenia Caused by the FOLFIRINOX Regimen].
    Kiba T; Saito Y; Otomo C; Sato M; Meguro T
    Gan To Kagaku Ryoho; 2016 Jul; 43(7):913-5. PubMed ID: 27431641
    [TBL] [Abstract][Full Text] [Related]  

  • 10. FOLFIRINOX as second-line chemotherapy for advanced pancreatic cancer: A subset analysis of data from a nationwide multicenter observational study in Japan.
    Kobayashi N; Omae K; Horita Y; Ueno H; Mizuno N; Uesugi K; Sudo K; Ozaka M; Hayashi H; Okano N; Kamei K; Yamaguchi A; Kobayashi S; Suzuki S; Ishihara S; Uchiyama T; Todaka A; Fukutomi A
    Pancreatology; 2020 Oct; 20(7):1519-1525. PubMed ID: 32972834
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prevention of chemotherapy-induced febrile neutropenia by prophylactic antibiotics plus or minus granulocyte colony-stimulating factor in small-cell lung cancer: a Dutch Randomized Phase III Study.
    Timmer-Bonte JN; de Boo TM; Smit HJ; Biesma B; Wilschut FA; Cheragwandi SA; Termeer A; Hensing CA; Akkermans J; Adang EM; Bootsma GP; Tjan-Heijnen VC
    J Clin Oncol; 2005 Nov; 23(31):7974-84. PubMed ID: 16258098
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Incidence of and risk factors for severe neutropenia during treatment with the modified FOLFIRINOX therapy in patients with advanced pancreatic cancer.
    Irisawa A; Takeno M; Watanabe K; Takahashi H; Mitsunaga S; Ikeda M
    Sci Rep; 2022 Sep; 12(1):15574. PubMed ID: 36114233
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A phase II study of modified FOLFIRINOX for chemotherapy-naïve patients with metastatic pancreatic cancer.
    Ozaka M; Ishii H; Sato T; Ueno M; Ikeda M; Uesugi K; Sata N; Miyashita K; Mizuno N; Tsuji K; Okusaka T; Furuse J
    Cancer Chemother Pharmacol; 2018 Jun; 81(6):1017-1023. PubMed ID: 29633005
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting tumour-associated macrophages with CCR2 inhibition in combination with FOLFIRINOX in patients with borderline resectable and locally advanced pancreatic cancer: a single-centre, open-label, dose-finding, non-randomised, phase 1b trial.
    Nywening TM; Wang-Gillam A; Sanford DE; Belt BA; Panni RZ; Cusworth BM; Toriola AT; Nieman RK; Worley LA; Yano M; Fowler KJ; Lockhart AC; Suresh R; Tan BR; Lim KH; Fields RC; Strasberg SM; Hawkins WG; DeNardo DG; Goedegebuure SP; Linehan DC
    Lancet Oncol; 2016 May; 17(5):651-62. PubMed ID: 27055731
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Risks and consequences of travel burden on prophylactic granulocyte colony-stimulating factor administration and incidence of febrile neutropenia in an aged Medicare population.
    Stephens JM; Bensink M; Bowers C; Hollenbeak CS
    Curr Med Res Opin; 2019 Feb; 35(2):229-240. PubMed ID: 29661043
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical Safety and Efficacy of Secondary Prophylactic Pegylated G-CSF in Advanced Pancreatic Cancer Patients Treated with mFOLFIRINOX: A Single-center Retrospective Study.
    Yamao K; Takenaka M; Yoshikawa T; Ishikawa R; Okamoto A; Yamazaki T; Nakai A; Omoto S; Kamata K; Minaga K; Hagiwara S; Sakurai T; Nishida N; Chiba Y; Watanabe T; Kudo M
    Intern Med; 2019 Jul; 58(14):1993-2002. PubMed ID: 30996164
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparative effectiveness of colony-stimulating factors for febrile neutropenia: a retrospective study.
    Tan H; Tomic K; Hurley D; Daniel G; Barron R; Malin J
    Curr Med Res Opin; 2011 Jan; 27(1):79-86. PubMed ID: 21091127
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Febrile neutropenia incidence and hematological toxicity with the FEC100-docetaxel regimen in the treatment of early-stage breast cancer.
    Cousin S; Le Rhun E; Mailliez A; Fournier C; Bonneterre J
    Bull Cancer; 2012; 99(7-8):75-80. PubMed ID: 22713627
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Single-center risk factor analysis for FOLFIRINOX associated febrile neutropenia in patients with pancreatic cancer.
    Keum J; Lee HS; Kang H; Jo JH; Chung MJ; Park JY; Park SW; Song SY; Bang S
    Cancer Chemother Pharmacol; 2020 Apr; 85(4):651-659. PubMed ID: 32185483
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prophylactic administration of granulocyte colony-stimulating factor in epirubicin and cyclophosphamide chemotherapy for Japanese breast cancer patients: a retrospective study.
    Sakurada T; Bando S; Zamami Y; Takechi K; Chuma M; Goda M; Kirino Y; Nakamura T; Teraoka K; Morimoto M; Tangoku A; Ishizawa K
    Cancer Chemother Pharmacol; 2019 Nov; 84(5):1107-1114. PubMed ID: 31502114
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.